Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zhaoke Ophthalmology Ltd. has secured marketing authorizations from China’s National Medical Products Administration for three new glaucoma drugs, expanding its comprehensive product portfolio for intraocular pressure management. With these additions, including Latanoprost, Travoprost, and Travoprost Timolol eye drops, the company aims to offer a broader selection for treating glaucoma patients in China, where the condition is highly prevalent. This development positions Zhaoke Ophthalmology to better serve the growing demand in the Chinese market.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.